| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | - |
| Drug | Agomelatine |
| Brand | Valdoxan® |
| Indication | For the treatment of major depressive disorder. |
| Assessment Process | |
| Full submission received from Applicant | 01/04/2009 |
| NCPE assessment completed | 03/09/2009 |
| NCPE assessment outcome | Reimbursement not recommended |
3rd September 2009 – At the current price agomelatine (Valdoxan®) is not considered cost-effective for the treatment of major depressive episodes under the Community Drugs Schemes.
11th December 2009 – Following a revision in price application we now consider agomelatine (Valdoxan®) cost effective under the Community Drugs schemes. The product will now be added to the list of items reimbursable under the schemes.